Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Investigational New Drugs
|
May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
European Journal of Pharmacology
|
April 15, 2014
VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats
Abhijit M Godbole, Senthilmurugan Ramalingam, Vidya P Ramamurthy, et al.
Leukemia & Lymphoma
|
July 21, 2025
BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
Cesar Rodriguez, Tulio Rodriguez, Alain Kentos, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 20, 2019
Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model
Yuan Chen, Tamara D Cabalu, Ernesto Callegari, et al.
Clinical Pharmacology and Therapeutics
|
November 20, 2023
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR-T and TCR-T Cellular Therapies Development
Jochem Gokemeijer, Nanda Balasubramanian, Ken Ogasawara, et al.
Clinical Pharmacology and Therapeutics
|
March 23, 2024
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program
Gerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, et al.
Clinical Pharmacology and Therapeutics
|
October 17, 2021
Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective
Chunze Li, Rajeev Menon, Markus Walles, et al.
Clinical Pharmacology and Therapeutics
|
December 3, 2020
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
Tycho Heimbach, Yuan Chen, Jun Chen, et al.
Molecular Therapy. Methods & Clinical Development
|
September 12, 2022
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Tong-Yuan Yang, Manuela Braun, Wibke Lembke, et al.
Blood
|
April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma
Hans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Investigational New Drugs
|
May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
European Journal of Pharmacology
|
April 15, 2014
VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats
Abhijit M Godbole, Senthilmurugan Ramalingam, Vidya P Ramamurthy, et al.
Leukemia & Lymphoma
|
July 21, 2025
BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
Cesar Rodriguez, Tulio Rodriguez, Alain Kentos, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 20, 2019
Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model
Yuan Chen, Tamara D Cabalu, Ernesto Callegari, et al.
Clinical Pharmacology and Therapeutics
|
November 20, 2023
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR-T and TCR-T Cellular Therapies Development
Jochem Gokemeijer, Nanda Balasubramanian, Ken Ogasawara, et al.
Clinical Pharmacology and Therapeutics
|
March 23, 2024
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program
Gerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, et al.
Clinical Pharmacology and Therapeutics
|
October 17, 2021
Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective
Chunze Li, Rajeev Menon, Markus Walles, et al.
Clinical Pharmacology and Therapeutics
|
December 3, 2020
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
Tycho Heimbach, Yuan Chen, Jun Chen, et al.
Molecular Therapy. Methods & Clinical Development
|
September 12, 2022
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Tong-Yuan Yang, Manuela Braun, Wibke Lembke, et al.
Blood
|
April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma
Hans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Page
of 7